Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioLineRx acquires Biokine's CXCR4 antagonist but switches target to leukaemia

This article was originally published in Scrip

Executive Summary

BioLineRx has met a recent goal of adding an oncology asset to its pipeline and continued to fulfil its stated mission of filling the gap between basic research and late-stage development - especially among its Israeli colleagues - by licensing the worldwide rights to Biokine Therapeutics' BKT-140, now known as BL-8040.

You may also be interested in...



Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow

Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.

ImmPACT Raises $110m As Bispecific CAR-T Shows Promising Response Rates

ImmPACT Bio is advancing three CAR-T technology platforms that aim to address problems such as antigen escape, off-target toxicities and the immunosuppressive tumor microenvironment. 

Finance Watch: SPACs Lose Their Luster As Difficulties Mount

Public Company Edition: While panelists at Biotech Showcase argued merging with a special purpose acquisition corporation is not as attractive as it used to be, firms continue to pursue this go-public alternative. Also, Hillstream launched a small IPO and Cytokinetics accessed cash from Royalty Pharma. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC018655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel